📰 Cor Pharma News
Page 4 - Cor Pharma News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Cor Pharma. Real-time updates on events, politics, business and more.
August 22, 2022
22.08.2022 - WALTHAM, Mass., Aug. 22, 2022 (GLOBE NEWSWIRE) - CinCor Pharma, Inc. (NASDAQ: CINC) today announced that the company will present Phase 1 clinical data on lead candidate baxdrostat as part of a poster presentation at the upcoming European Society ... Seite 1
August 15, 2022
WALTHAM, Mass., Aug. 15, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (“CinCor”) (Nasdaq: CINC), a clinical-stage biopharmaceutical company focused on...
August 11, 2022
WALTHAM, Mass., Aug. 11, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (“CinCor”) (Nasdaq: CINC), a clinical-stage biopharmaceutical company focused on...
August 11, 2022
11.08.2022 - WALTHAM, Mass., Aug. 11, 2022 (GLOBE NEWSWIRE) - CinCor Pharma, Inc. (“CinCor”) (Nasdaq: CINC), a clinical-stage biopharmaceutical company focused on developing its lead clinical candidate, baxdrostat, for the treatment of hypertension and other ... Seite 1
August 8, 2022
Positive topline data in the Phase 2 BrigHtn trial, demonstrating clinically meaningful and statistically significant reduction in blood pressure with baxdrostat in treatment-resistant hypertension ... | August 8, 2022
June 1, 2022
CinCor Pharma is uncovering a great potential for combatting treatment-resistant and uncontrolled hypertension.

May 20, 2022
Brokerages expect CinCor Pharma, Inc. (NASDAQ:CINC – Get Rating) to report ($0.50) earnings per share for the current quarter, according to Zacks Investment Research. Zero analysts have provided estimates for CinCor Pharma’s earnings. The highest EPS estimate is ($0.43) and the lowest is ($0.55). The company is expected to report its next quarterly earnings report […]
April 21, 2022
We have used the quarterly return data of companies that went public in Q1 2022 to rank the ten best performing IPOs in Q1 2022.
April 11, 2022
Brokerages expect CinCor Pharma, Inc. (NASDAQ:CINC – Get Rating) to announce earnings per share of ($0.50) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for CinCor Pharma’s earnings, with the highest EPS estimate coming in at ($0.44) and the lowest estimate coming in at ($0.59). The business is scheduled to […]
March 24, 2022
CinCor Pharma (NASDAQ:CINC – Get Rating) posted its earnings results on Tuesday. The company reported ($15.71) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.56) by ($14.15), MarketWatch Earnings reports. NASDAQ CINC traded up $0.09 on Thursday, hitting $15.39. 344 shares of the company traded hands, compared to its average volume of 247,779. […]